Quality by design–based development and optimization of fourth-generation ternary solid dispersion of standardized Piper longum extract for melanoma therapy

• Published in: Drug delivery and translational research Vol. 13; no. 12; pp. 3094 - 3131
• Main Authors: Mohapatra, Debadatta, Kumar, Dulla Naveen, Shreya, Singh, Pandey, Vivek, Dubey, Pawan K., Agrawal, Ashish Kumar, Sahu, Alakh N
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-12-2023
• Subjects: Biomedical and Life Sciences; Biomedicine; Original Article; Pharmaceutical Sciences/Technology; Solid dispersion; Bioavailability; Dissolution; Optimization; Melanoma
• ISSN: 2190-393X; 2190-3948
• DOI: 10.1007/s13346-023-01375-y

The study aimed to enhance the solubility, dissolution, and oral bioavailability of standardized
Piper longum
fruits ethanolic extract (PLFEE) via fourth-generation ternary solid dispersion (SD) for melanoma therapy. With the use of solvent evaporation method, the standardized PLFEE was formulated into SD, optimized using Box-Wilson’s central composite design (CCD), and evaluated for pharmaceutical performance and in vivo anticancer activity against melanoma (B16F10)–bearing C57BL/6 mice. The optimized SD showed good accelerated stability, high yield, drug content, and content uniformity for bioactive marker piperine (PIP). The X-ray diffraction (XRD), differential scanning calorimetry (DSC), polarized light microscopy (PLM), and selected area electron diffraction (SAED) analysis revealed its amorphous nature. The attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) and high-performance thin layer chromatography (HPTLC) revealed the compatibility of excipients with the PLFEE. The contact angle measurement and in vitro dissolution study revealed excellent wetting of SD and improved dissolution profile as compared to the plain PLFEE. The in vivo oral bioavailability of SD reflected a significant (
p
 < 0.05) improvement in bioavailability (
F
rel
 = 188.765%) as compared to plain extract. The in vivo tumor regression study revealed the improved therapeutic activity of SD as compared to plain PLFEE. Further, the SD also improved the anticancer activity of dacarbazine (DTIC) as an adjuvant therapy. The overall result revealed the potential of developed SD for melanoma therapy either alone or as an adjuvant therapy with DTIC.
Graphical Abstract